A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy of a Nutritional Supplement in Female Androgenic Alopecia

The clinical trial involved 47 women aged 25-59 years with initial to moderate Androgenetic alopecia (AGA), with 24 receiving a nutritional supplement, Pilopeptan® WOMAN 5αR (PPT5α), and 23 receiving a placebo. After 6 months, the PPT5α group showed higher percentages of terminal hair in both the frontal (77.6% vs 69.8%) and parietal (77% vs 64.3%) areas compared to the placebo group. Self-assessments also showed improvements in hair loss reduction and hair thickness at both the 3-month and 6-month visits. The study concluded that PPT5α may be beneficial in preventing progression or even improving the condition of AGA in the early stages, with no significant adverse events reported. However, the study's limitations include a limited sample size and a relatively short follow-up period.